Stay updated on GEMINI 2 Tolebrutinib in RMS Clinical Trial
Sign up to get notified when there's something new on the GEMINI 2 Tolebrutinib in RMS Clinical Trial page.

Latest updates to the GEMINI 2 Tolebrutinib in RMS Clinical Trial page
- Check6 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record content, indicating an access restriction. This suggests a server-side issue or blocked access to the study record page.SummaryDifference17%

- Check13 days agoChange DetectedLocations list now includes Tel Litwinsky, Israel, 52621 as a new site and removes Qiryat Krinitzi, Israel, 52621 from the study locations.SummaryDifference0.1%

- Check20 days agoChange DetectedQiryat Krinitzi, Israel, 52621 was added as a study site and Tel Litwinsky, Israel, 52621 was removed, altering the geographic footprint of trial locations and potentially where participants can enroll.SummaryDifference0.1%

- Check27 days agoChange DetectedA new site revision label, Revision: v3.6.6, was added to the page, replacing the previous Revision: v3.6.5, indicating a deployed update.SummaryDifference0.0%

- Check48 days agoChange DetectedA new publication citation for Tolebrutinib liver safety was added and the page revision updated to v3.6.5. The plain language results summary, sponsor label, and Helpful Links section were removed as part of a UI/content cleanup.SummaryDifference0.1%

- Check63 days agoChange DetectedA new revision label Revision: v3.6.4 appears on the page, replacing the previous v3.6.3. This indicates a minor update to the page's version without altering the study details.SummaryDifference0.0%

Stay in the know with updates to GEMINI 2 Tolebrutinib in RMS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GEMINI 2 Tolebrutinib in RMS Clinical Trial page.